Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$0.00
$4.35
$11.97
$1.01B4.52528,025 shs1.43 million shs
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
$26.98
$26.96
$7.67
$27.06
$2.62B2.171.17 million shs2.26 million shs
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
$1.27
$0.85
$7.10
N/AN/AN/A87,682 shs
Omeros Corporation stock logo
OMER
Omeros
$3.42
+9.1%
$3.88
$2.95
$13.60
$199.50M2.16728,897 shs532,350 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.37
+0.4%
$1.32
$1.21
$2.04
$1.08B1.343.87 million shs1.67 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00%0.00%0.00%0.00%0.00%
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
0.00%0.00%0.00%0.00%0.00%
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
0.00%0.00%0.00%0.00%0.00%
Omeros Corporation stock logo
OMER
Omeros
+1.62%+5.39%-16.98%-51.85%-19.54%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+1.49%+2.26%0.00%-8.72%+5.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/AN/AN/AN/A
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
3.2764 of 5 stars
3.40.00.04.40.01.70.6
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.537 of 5 stars
3.42.00.04.42.25.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00
N/AN/AN/A
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
0.00
N/AN/AN/A
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
0.00
N/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
2.83
Moderate Buy$18.00427.09% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.75101.47% Upside

Current Analyst Ratings Breakdown

Latest ODT, OPK, OMER, CNTTF, and MYOV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
6/27/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/10/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
5/16/2025
Omeros Corporation stock logo
OMER
Omeros
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/13/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/7/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
4/11/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$15.96M0.00N/AN/AN/ANaN
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
$230.97M11.36N/AN/A($5.04) per share-5.35
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/AN/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/A($3.15) per shareN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
$689.41M1.57$0.07 per share19.48$2.00 per share0.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A$0.07137.180.00N/AN/AN/AN/AN/A
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/A
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
-$126.35MN/A0.00N/AN/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
-$156.82M-$2.65N/AN/AN/AN/AN/A-59.68%8/6/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.07N/AN/AN/A-5.66%-2.85%-1.82%8/6/2025 (Estimated)

Latest ODT, OPK, OMER, CNTTF, and MYOV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.46N/AN/AN/AN/AN/A
8/6/2025Q2 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.11N/AN/AN/A$165.74 millionN/A
5/15/2025Q1 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/A
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
N/AN/AN/AN/AN/A
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/A
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
N/A
1.57
1.45
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/A
1.16
1.16
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
2.49
2.28

Institutional Ownership

CompanyInstitutional Ownership
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.08%
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
30.62%
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/A
Omeros Corporation stock logo
OMER
Omeros
48.79%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
1.90%
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
48.90%
Omeros Corporation stock logo
OMER
Omeros
12.90%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A105.61 millionN/ANot Optionable
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
40797.24 million95.39 millionNot Optionable
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
14528.53 million14.58 millionNot Optionable
Omeros Corporation stock logo
OMER
Omeros
21058.59 million51.04 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.05 million398.99 millionOptionable

Recent News About These Companies

Q1 2025 OPKO Health Inc Earnings Call
OPKO Health: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CannTrust stock logo

CannTrust OTCMKTS:CNTTF

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Myovant Sciences stock logo

Myovant Sciences NYSE:MYOV

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Odonate Therapeutics stock logo

Odonate Therapeutics NASDAQ:ODT

Odonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').

Omeros stock logo

Omeros NASDAQ:OMER

$3.42 +0.29 (+9.11%)
As of 11:25 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.36 +0.01 (+0.37%)
As of 11:25 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.